Format

Send to

Choose Destination
Int J Psychiatry Clin Pract. 2017 Mar;21(1):2-12. doi: 10.1080/13651501.2016.1254802. Epub 2017 Jan 18.

Administration of ketamine for unipolar and bipolar depression.

Author information

1
a Department of Psychiatry and Psychotherapy , Medical University of Vienna , Vienna , Austria.
2
b Department of Adult Psychiatry , Poznan University of Medical Sciences , Poznan , Poland.

Erratum in

  • Erratum. [Int J Psychiatry Clin Pract. 2017]

Abstract

OBJECTIVE:

Clinical trials demonstrated that ketamine exhibits rapid antidepressant efficacy when administered in subanaesthetic dosages. We reviewed currently available literature investigating efficacy, response rates and safety profile.

METHODS:

Twelve studies investigating unipolar, seven on bipolar depression were included after search in medline, scopus and web of science.

RESULTS:

Randomized, placebo-controlled or open-label trials reported antidepressant response rates after 24 h on primary outcome measures at 61%. The average reduction of Hamilton Depression Rating Scale (HAM-D) was 10.9 points, Beck Depression Inventory (BDI) 15.7 points and Montgomery-Asberg Depression Rating Scale (MADRS) 20.8 points. Ketamine was always superior to placebo. Most common side effects were dizziness, blurred vision, restlessness, nausea/vomiting and headache, which were all reversible. Relapse rates ranged between 60% and 92%. To provide best practice-based information to patients, a consent-form for application and modification in local language is included.

CONCLUSIONS:

Ketamine constitutes a novel, rapid and efficacious treatment option for patients suffering from treatment resistant depression and exhibits rapid and significant anti-suicidal effects. New administration routes might serve as alternative to intravenous regimes for potential usage in outpatient settings. However, long-term side effects are not known and short duration of antidepressant response need ways to prolong ketamine's efficacy.

KEYWORDS:

Ketamine; NMDA-receptor; depression; glutamate; rapid antidepressant

PMID:
28097909
DOI:
10.1080/13651501.2016.1254802
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center